Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by increased blood glucose levels, i.e., hyperglycemia, which over time can cause microvascular and macrovascular complications \[[@CR1]\]. The main goal of T2DM treatment is to achieve and maintain patients' individual target blood glucose levels, thus reducing the occurrence of complications \[[@CR2]\].

There are several guidelines for the management of T2DM including those developed by the International Diabetes Federation (IDF) \[[@CR3]\], the American Diabetes Association (ADA) \[[@CR4]\], the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) \[[@CR5]\], and the National Institute of Health and Care Excellence (NICE) from the UK \[[@CR6]\]. The treatment recommendations are generally consistent but with some differences. For example, the ADA and the European Association for the Study of Diabetes (EASD) suggest a treatment algorithm for patients with T2DM \[[@CR7]\] which suggests that patients with T2DM should initially be offered education in lifestyle changes, with advice to lose weight by changing dietary habits and increasing physical activity. If a patient's blood glucose level is not decreased to, and maintained at, the individualized target glycated hemoglobin (HbA1c) levels \[[@CR7]\], it is recommended that medical treatment with anti-diabetic drugs be initiated. Over the years, glucagon-like peptide (GLP-1) receptor agonists (RAs) have become integral as second- or third-line therapies in many treatment guidelines, such as the ADA/EASD, the AACE, and the IDF \[[@CR3]--[@CR7]\].

GLP-1 RAs are one among many treatment options available for patients with T2DM. GLP-1 RAs mimic the effects of endogenous GLP-1, which regulates plasma glucose levels by stimulating the secretion and biosynthesis of insulin and by inhibiting the secretion of glucagon and by delaying the gastric emptying of food and reducing food intake \[[@CR8], [@CR9]\]. Based on this mechanism of action, GLP-1 RA has effects on controlling glucose level and reducing body weight. Liraglutide was the second GLP-1 RA that was approved for the treatment of T2DM by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in 2009 and 2010, respectively. Currently, liraglutide is the most used GLP-1 RA worldwide \[[@CR10]\]. The efficacy and safety of liraglutide mono- and combination therapy have been evaluated in the Liraglutide Effect and Action in Diabetes (LEAD) clinical program which consisted of six clinical trials \[[@CR11]--[@CR16]\], and recently a clinical trial comparing liraglutide head-to-head with lixisenatide was finalized \[[@CR17]\]. There exist a number of different clinical trials on the efficacy of liraglutide, among others comparative trials vs. albiglutide \[[@CR18]\], dulaglutide \[[@CR19]\], exenatide \[[@CR20]\], sitagliptin \[[@CR21], [@CR22]\], switching to GLP-1 RA from sitagliptin \[[@CR23]\] and with other oral antidiabetic drugs (OADs; dipeptidyl peptidase-4 inhibitors \[DPP-4i\], sulfonylurea \[SU\], glinide, metformin \[MET\], α-glucosidase inhibitor, or thiazolidinedione \[TZD\]) \[[@CR24]\]. Furthermore, one Japanese trial assessed liraglutide in combination with insulin \[[@CR25]\]. Results from all these trials consistently showed that patients treated with liraglutide had significantly improved glycemic control (with a high proportion of patients reaching HBA1c \<7.0% at the end of the trial) and achieved substantial reductions in absolute body weight. Importantly, these beneficial effects of liraglutide occurred with a low risk of hypoglycemia, and the drug was well tolerated in patients with T2DM \[[@CR11]--[@CR25]\].

Established as a drug with robust clinical efficacy and safety profile in controlled settings, the clinical effectiveness and safety of liraglutide for the treatment of patients with T2DM have also been investigated in observational studies reflecting real-life clinical practice. We performed a systematic literature review to evaluate the effectiveness of liraglutide for the treatment of patients with T2DM in real-world clinical practice. The goal of the review is to provide a succinct overview of the evidence on the clinical effectiveness of liraglutide which could help guide clinical decision making and assist clinicians in deciding how different therapies fit into the current treatment algorithm, and help inform current and future treatment guidelines for the management of patients with T2DM.

Methods {#Sec2}
=======

This systematic literature review was conducted in accordance with the NICE guidance to obtain relevant information using a consistent, reproducible, and transparent methodology \[[@CR26]\]. According to this guidance, this process involves the development of a study protocol (see supplementary file 1), parallel review of retrieved publications by two independent researchers for the selection of relevant publications, followed by a full-evidence data extraction and quality assessment of study methodology, results, and implication of results to routine T2DM clinical practice.

Search Strategy {#Sec3}
---------------

To collect evidence on the effectiveness of liraglutide, different databases were selected. These included Medline (1979--2016) and EMBASE (1974--2016; searched simultaneously via ProQuest), Cochrane (1992--2016; Cochrane Database of Systematic Reviews \[CDSR\]; Database of Abstracts of Reviews of Effects \[DARE\]; Cochrane Methodology Register \[CMR\]; Health Technology Assessments Database \[HTA\]; and The National Health Services \[NHS\] Economic Evaluation Database \[EED\]), health technology assessment websites, and conference proceedings (International Society for Pharmacoeconomics and Outcomes Research \[ISPOR\], ADA, EASD, World Diabetes Congress-IDF \[WDC-IDF\]).

The search terms included both free-text and Emtree/MeSH terms of indication, clinical effectiveness, comparative effectiveness, generic and brand name of liraglutide, and were designed to meet the requirements outlined in NICE guidelines for the methods of technology appraisal \[[@CR26]\]. Complex search strings, combining extensive lists of search terms for indication and topic, were used to search the databases through ProQuest. For other databases, less complex search strings were used as the search engines provided fewer options. In all databases, no language or time limits were applied to ensure that no relevant publications were missed. The annual meeting abstracts were only searched for the last 3 years (up until 2015), because it was assumed that after 3 years these would have been published as full publications in a peer-reviewed journal. The search terms that were applied per database are provided in the study protocol (see supplementary file 1).

The database searches were executed on October 13, 2015 and an updated search in ProQuest was conducted on January 7, 2016.

Eligibility Criteria {#Sec4}
--------------------

After all the searches were performed, the results were screened (based on title and abstract followed by full-text review) in parallel by two independent researchers after the removal of duplicate publications. If the researchers could not reach agreement on the selection of a relevant publication, a third independent researcher was consulted to decide eligibility of the publication for the review. The inclusion and exclusion criteria for the screening and selection process are provided in Table [1](#Tab1){ref-type="table"}.Table 1Study eligibility criteriaItemInclusion criteriaExclusion criteriaPopulationPatients with T2DMType 1 diabetes mellitus\
Gestational diabetes\
Other diseasesInterventionTreatment regimens including liraglutideInsulin therapy\
NIADsComparatorTreatment regimens including NIADs\
 TZD (e.g., pioglitazone)\
 DPP-4i (e.g., sitagliptin or saxagliptin)\
SGLT2 inhibitor (e.g., dapagliflozin or canagliflozin)\
 GLP-1 RA (e.g., exenatide, albiglutide, or dulaglutide)\
 MET\
 SU\
 Other OADsInsulin therapyOutcomesClinical effectiveness and safety of liraglutide\
Comparative effectiveness and safety of liraglutide compared to other NIADsStudies not reporting the clinical effectiveness/safety of either liraglutide compared to other NIADsStudy designChart review\
Medical record analysis\
Database analysis\
Expert panel studies\
Prospective follow-up studies\
Post-marketing surveillance studiesRCT\
Case-reports\
Letters to editorLocationAllNoneLanguageAllNone*DPP*-*4i* dipeptidyl peptidase-4 inhibitor, *GLP* glucagon-like peptide, *MET* metformin, *NIAD* non-insulin antidiabetic drug, *OAD* oral antidiabetic drug, *RA* receptor agonist, *RCT* randomized controlled trials, *SGLT2* sodium-glucose cotransporter type-2, *SU* sulfonylurea, *T2DM* type 2 diabetes mellitus, *TZD* thiazolidinedione

Data Extraction and Assessment of Study Quality {#Sec5}
-----------------------------------------------

The data extraction of selected studies was performed by one researcher (AO). A second researcher performed a thorough quality check to assure all relevant data were extracted to the correct parameter (WX). Endpoints for data extraction were decided a priori. These primarily included effectiveness (glucose control and weight) and if the studies identified in the literature search reported safety endpoints (hypoglycemia, adverse events \[AEs\], serious AEs) related to liraglutide treatment for patients with T2DM, then these were also included. No statistical analyses were performed.

Following data extraction, a critical appraisal of the quality of selected studies was performed by a single researcher (AO), and reviewed by a second researcher (WX). This quality assessment was completed for all selected observational studies that were published in full text based on the recommendations of the Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews in healthcare \[[@CR27]\]. The quality of full-text publications was subjectively evaluated based on several criteria including completeness of reporting, study population and design, sample size, sampling procedure, study follow-up duration, treatment setting, patient inclusion and exclusion criteria and patient enrollment and study completion rates. In addition to this, quality appraisal was further informed by assessing potential sources of confounding and biases (e.g., patient baseline characteristics, misclassification, selection bias, reporting bias, etc.) which are known to be prominent in observation studies. The limitations described in the individual articles from the authors' perspective were also used to guide the quality appraisal. The quality assessment of abstracts was not performed as study details were not adequately reported.

Data Reporting {#Sec6}
--------------

The results section focuses mainly on the findings from full-text journal publications identified in the systematic literature review. These findings are supplemented with supportive evidence from the conference abstracts. This approach for presentation was chosen because full-text publications are peer reviewed and considered to be of higher quality than abstracts from annual conference proceedings as complete methodological details and results are reported in full-text articles.

Compliance with Ethics Guidelines {#Sec7}
---------------------------------

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec8}
=======

Included Studies {#Sec9}
----------------

The database searches resulted in 220 publications from Medline and EMBASE (via ProQuest). No publications were identified in the Cochrane library. A total of 303 publications were found from conference proceedings. After removing 88 duplicates from a total of 523 publications, the title and abstracts of 435 publications were screened for eligibility to a full-text screening. Of 435 publications, 284 were excluded based on title and abstract screening. Of 151 publications, 81 were abstracts from conference proceedings and, therefore, only 70 full-text publications were reviewed for eligibility by full-text screening based on the pre-defined study eligibility criteria. Of these 70 full-text publications, 27 were excluded: 5, 17, and 5 records due to population, outcome, and study design irrelevance, respectively. Thus, 43 full-text publications were included.

One-hundred and twenty-four publications were eventually included in this literature review. Of these, 43 were full-text journal articles, and 81 were abstracts identified from databases of conference proceedings or from published supplements of conference proceedings. The search and selection procedure is shown in the PRISMA flowchart (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PRISMA flow diagram. No studies were excluded due to intervention/comparator at the full-text screening stage. Other sources include publications from different conference proceedings (see supplementary file 1). ^a^Patients were solid organ transplant recipients or had other serious comorbidities. ^b^Results were reported for overall glucagon-like peptide-1 receptor agonist (no differentiation for liraglutide and exenatide); or data were unavailable in the full-text article. *ti, ab* title and abstract

Study Characteristics {#Sec10}
---------------------

More than half of the 43 full-text journal articles \[[@CR28]--[@CR70]\] had a study design which involved analyses of data that were previously collected from patient medical record/chart review from hospitals, or databases (53.5%; *N* = 23) \[[@CR28], [@CR30]--[@CR33], [@CR37], [@CR39], [@CR40], [@CR43], [@CR44], [@CR46], [@CR49]--[@CR51], [@CR54]--[@CR58], [@CR61], [@CR62], [@CR65], [@CR70]\]. The majority of the studies assessed the clinical effectiveness of liraglutide without an active comparator (81.4%; *N* = 35) \[[@CR28], [@CR29], [@CR31], [@CR34], [@CR36]--[@CR39], [@CR41]--[@CR49], [@CR51]--[@CR55], [@CR57], [@CR60]--[@CR64], [@CR66]--[@CR71]\]. Real-world studies with comparators were less frequently observed (18.6%; *N* = 8); the most common comparators for liraglutide were: sitagliptin or any DPP-4i (*N* = 6) \[[@CR32], [@CR33], [@CR35], [@CR40], [@CR56], [@CR58]\], exenatide (*N* = 3) \[[@CR33], [@CR35], [@CR50]\], glimepiride or any other SUs (*N* = 2) \[[@CR30], [@CR35]\], pioglitazone or other TZDs (*N* = 1) \[[@CR35]\], and MET (*N* = 1) \[[@CR35]\]; note: these numbers do not add up because some studies had more than one comparator. The most frequently observed follow-up duration from these publications was ≥12 months (46.5%; *N* = 20) \[[@CR28]--[@CR47]\], followed by 6--12 months (34.9%; *N* = 15) \[[@CR48]--[@CR62]\], and \<6 months (18.6%; *N* = 8) \[[@CR63]--[@CR70]\]. Real-world studies frequently reported data on the effect of liraglutide from outpatient settings (30.2%; *N* = 13) \[[@CR34], [@CR39], [@CR40], [@CR42]--[@CR44], [@CR49], [@CR55], [@CR58], [@CR60], [@CR61], [@CR66], [@CR67]\]. The geographical scope of the review included studies from Europe (*N* = 24), the USA (*N* = 5), and Asia--Pacific (*N* = 14; see supplementary file 2).

Study characteristics from the abstracts (*N* = 81; see supplementary file 3 for the full list of conference abstracts included in this review) were similar to those reported from full-text publications. The majority of conference abstracts reported findings from studies involving analyses of already available data (60.5%; *N* = 49), followed by those based on prospective study designs (24.7%; *N* = 20). For the remaining abstracts (14.8%; *N* = 12), information on study design was not reported. Most of the studies assessed liraglutide without an active comparator (75.3%; *N* = 61). The common comparators were exenatide (*N* = 9), sitagliptin or any DPP-4i (*N* = 8), and glimepiride (*N* = 2). The most frequent follow-up duration in the studies was ≥12 months (*N* = 36), followed by ≥6--12 months (*N* = 27), and \<6 months (*N* = 13). Five studies did not have information on study duration. The treatment effect of liraglutide from outpatient and inpatient settings was reported in 16 and 2 studies, respectively. The remaining abstracts did not specify the treatment setting.

Quality Appraisal of Full-Text Articles {#Sec11}
---------------------------------------

Findings from the quality appraisal of 43 full-text journal publications are presented in supplementary file 4. Generally, the study designs were appropriate to assess the clinical effectiveness of liraglutide in routine clinical practice. The review findings allow understanding of the outcomes from real-world clinical practice when liraglutide is prescribed according to local guidelines.

Common limitations of some of the studies that were identified included small sample size, missing data, and limited generalizability to the patient setting or study country. Some studies did not adjust for potential confounding by measured and unmeasured factors like prescription bias. Confounding variables such as the use of other medications, baseline severity of disease and duration of diabetes, values of comorbidity indices, baseline prevalence of comorbidities, and body mass index (BMI) were also not addressed between intervention and comparator groups. Notably, these study limitations are typically reported in observational studies \[[@CR72]\].

Patient Baseline Characteristics {#Sec12}
--------------------------------

In the full-text publications (*N* = 43), 7413 patients were treated with liraglutide. The mean age of patients with T2DM on liraglutide treatment was between 43.6 and 63.5 years at baseline. The majority of publications (*N* = 22) included more male patients (50.5--74.4%) than female patients. In the remaining 21 studies, male patients comprised 29.0--49.4% of the total study population. Mean duration of T2DM ranged from 5 to 15.8 years. The mean baseline HbA1c level of patients with T2DM before liraglutide treatment was between 7.2% and 9.8%. Mean baseline weight and mean BMI were 63.8--120 kg and 24.7--38.6 kg/m^2^, respectively (see supplementary file 2).

The average dosage of liraglutide varied by country (dosage information was not available for 9 publications \[[@CR32], [@CR35], [@CR46], [@CR49]--[@CR51], [@CR56], [@CR58], [@CR70]\]). In all the studies from Japan, patients were started at a dosage of 0.3 mg per day and titrated up to 0.9 mg per day in increments of 0.3 mg per week \[[@CR38], [@CR40], [@CR54], [@CR55], [@CR61], [@CR68], [@CR70]\]. The recorded liraglutide dose used in real-world studies was higher in the USA than in Europe, as 1.8 mg was used more often than 1.2 mg \[[@CR28], [@CR49], [@CR56], [@CR73]\]. In Europe, the use of both 1.2 and 1.8 mg doses of liraglutide was documented. Notably, most of the patients from European studies received liraglutide 1.2 mg, and a subgroup of patients in these studies had the dose escalated to 1.8 mg.

In studies comparing liraglutide with active comparators, baseline patient characteristics were generally balanced between treatment groups. Some differences were observed in the baseline characteristics, especially regarding use of concomitant and previous antidiabetic therapy. Concomitant SU, MET, and, to an extent, basal/pre-mixed insulin use was similar in patients treated with exenatide or liraglutide. There was insufficient information on the use of concomitant medications in patients using DPP-4i or pioglitazone compared to liraglutide. Information on the use of prior therapies varied between the studies.

Patient characteristics from conference abstracts largely showed a similar trend to those observed for patient baseline characteristics from full-text articles.

Clinical Effectiveness {#Sec13}
----------------------

### Glucose Control {#Sec14}

#### HbA1c: Change in HbA1c Level {#Sec15}

The clinical effectiveness of antidiabetic drugs on blood glucose control is measured by HbA1c (which is widely used as a measure of average glucose level over the preceding months before the time of measurement) and/or plasma glucose level (either fasting or post-prandial) \[[@CR6], [@CR74]\].

The following measurements were reported by the identified observational studies regarding HbA1c level: change in mean HbA1c from baseline to end-of-study, and proportion of patients achieving widely accepted HbA1c targets for patients with T2DM (i.e., \<7% or ≤6.5%).

One-hundred and six publications reported the changes in HbA1c from baseline to end-of-study, for patients with T2DM treated with liraglutide. Of these, 38 were full-text articles \[[@CR28]--[@CR34], [@CR36]--[@CR53], [@CR55]--[@CR60], [@CR62], [@CR64], [@CR66], [@CR67], [@CR69], [@CR70]\]. Study attributes and patient baseline characteristics from the included studies are provided in supplementary file 2. Of the 38 full-text publications, 18 studies reported an average follow-up duration of ≥12 months \[[@CR29]--[@CR33], [@CR36]--[@CR40], [@CR42]--[@CR47]\], followed by 15 studies with an average follow-up period of ≥6--12 months \[[@CR34], [@CR48], [@CR49], [@CR52]--[@CR60], [@CR62], [@CR73]\]. The remaining five studies had an average follow-up period of ≤6 months \[[@CR64], [@CR66], [@CR67], [@CR69], [@CR70]\].

The identified studies reported mean baseline HbA1c in the range of 7.5--9.8% and end-of-study HbA1c ranging from \<6% to 8.5% after liraglutide treatment \[[@CR29]--[@CR34], [@CR36]--[@CR50], [@CR52]--[@CR60], [@CR62], [@CR64], [@CR66], [@CR67], [@CR69], [@CR70]\]. It was reported that liraglutide therapy led to a mean HbA1c change from baseline of −0.6% to −2.26% (see Fig. [2](#Fig2){ref-type="fig"}). Mean changes in HbA1c from baseline to end-of-study from studies conducted in Europe (*N* = 21), the USA (*N* = 4), and Asia--Pacific (*N* = 13) were −0.8% to −1.9%, −0.8% to −0.99%, and −0.6% to −2.26%, respectively (see Fig. [2](#Fig2){ref-type="fig"}). Real-world studies demonstrate evidence of lowering blood glucose levels regardless of baseline HbA1c level and follow-up durations in patients with T2DM treated with liraglutide (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR28]--[@CR34], [@CR36]--[@CR53], [@CR55]--[@CR60], [@CR62], [@CR64], [@CR66], [@CR67], [@CR69], [@CR70]\].Fig. 2Mean change in HbA1c from baseline in patients with T2DM on liraglutide treatment in **a** Europe (*N* = 21), **b** the USA (*N* = 4), and **c** Asia--Pacific (*N* = 13). ^a^\[[@CR11]--[@CR25]\]. Note: data in the figures report findings from full-text publications (38 of the 43 articles that were included in the review). Data on HbA1c were not reported in five full-text publications. *Numbers in parentheses* on the *x axis* are references to the relevant publications. *HbA1c* glycated hemoglobin, *T2DM* type 2 diabetes mellitus

#### HbA1c: Proportion of Patients Achieving HbA1c Target of \<7% and ≤6.5% {#Sec16}

The guidelines of the ADA (2015) \[[@CR2]\] and Canadian Diabetes Association (CDA) suggest multiple goals of therapy, including attaining the composite endpoint of HbA1c \< 7%, no incidence of hypoglycemia, and/or no weight gain (or weight loss if obese) in patients with T2DM. More or less stringent targets may be appropriate if these can be achieved without significant hypoglycemia or AEs. The AACE recommend a stringent glycemic target of HbA1c ≤6.5% with low risk of hypoglycemia \[[@CR75]\], which is further endorsed by NICE \[[@CR74]\]. A total of 37 publications had data on the proportion of patients achieving the HbA1c targets of \<7.0% and ≤6.5%.

Overall, 29.3--64.5% \[[@CR28]--[@CR32], [@CR34], [@CR36], [@CR39], [@CR42], [@CR43], [@CR45], [@CR46], [@CR48], [@CR49], [@CR52]--[@CR54], [@CR56]--[@CR58], [@CR70], [@CR73]\] and 22.05--41.03% \[[@CR28], [@CR42], [@CR45], [@CR49], [@CR52], [@CR53], [@CR56]\] patients with T2DM treated with liraglutide met the \<7% and ≤6.5% HbA1c targets, respectively (for baseline characteristics of study population in these studies; see supplementary file 2).

#### Fasting and Post-Prandial Plasma Glucose {#Sec17}

Thirty-six publications reported data on the effect of liraglutide on fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG). Of these, 20 were full-text articles. Baseline FPG and PPG levels in patients with T2DM treated in the real-world setting were 114.4--201 mg/dL and 167.57--252.5 mg/dL, respectively. Overall, the evidence indicated that liraglutide monotherapy and/or in combination with oral glucose-lowering agents was effective in reducing FPG and PPG levels. FPG and PPG reductions from baseline to end-of-study were in the range of 28.1--52.21 and 23.7--66.71 mg/dL, respectively. End-of-study FPG and PPG observations ranged from 99.1--144 and 100.9--180.7 mg/dL, which are close to the ADA-recommended glycemic target for non-pregnant adults (70--130 and \<180 mg/dL, respectively) \[[@CR76]\].

### Body Weight {#Sec18}

Reduction in body weight is associated with improved glycemic control, insulin sensitivity, and a reduced risk of developing cardiovascular disease in obese patients with diabetes \[[@CR77]\].

Seventy-four publications reported effect of liraglutide on body weight in patients with T2DM. Among these, 28 were full-text publications \[[@CR29]--[@CR32], [@CR34], [@CR36], [@CR37], [@CR39], [@CR40], [@CR42], [@CR43], [@CR46], [@CR48], [@CR49], [@CR51]--[@CR55], [@CR57]--[@CR59], [@CR62], [@CR63], [@CR65], [@CR67], [@CR69]\]. Only 4 studies had a follow-up period of \<6 months \[[@CR63], [@CR65], [@CR67], [@CR69]\]. The remaining studies were equally divided between study follow-up durations of ≥6--12 months (*N* = 12) \[[@CR34], [@CR48], [@CR49], [@CR51]--[@CR55], [@CR57]--[@CR59], [@CR62]\] and ≥12 months (*N* = 12) \[[@CR29]--[@CR32], [@CR36], [@CR37], [@CR39], [@CR40], [@CR42], [@CR43], [@CR46], [@CR62]\].

Overall, liraglutide treatment both as monotherapy and in combination with oral therapy led to significant weight loss in patients with T2DM (Fig. [3](#Fig3){ref-type="fig"}). In patients with T2DM who were prescribed liraglutide therapy baseline weight and BMI range were 63.8--120 kg/m^2^ and 24.7--38.6 kg/m^2^, respectively.Fig. 3Mean reduction in weight from baseline in patients with T2DM on liraglutide treatment in **a** Europe (*N* = 16), **b** the USA (*N* = 1), and **c** Asia--Pacific (*N* = 11). ^a^\[[@CR11]--[@CR25]\]. Note: data in the figure report findings from 28 full-text publications (28 of the 43 articles that were included in the review). Data on weight were not reported in 15 full-text publications. *Numbers in parentheses* on the *x* *axis* are references to the relevant publications. *T2DM* type 2 diabetes mellitus

Liraglutide therapy, over time, led to a mean change in absolute weight from baseline of −1.3 to −8.65 kg. Mean changes in weight from baseline in patients from Europe (*N* = 16), the USA (*N* = 1), and Asia--Pacific (*N* = 11) were −2.4 to −6.5 kg, −2.9 kg, and −1.3 to −8.7 kg, respectively (Fig. [3](#Fig3){ref-type="fig"}). A few studies showed mean weight reduction in patients with T2DM for up to 2 years after initiating liraglutide treatment \[[@CR30], [@CR40], [@CR42], [@CR43], [@CR78]\].

Two studies that included 3210 patients showed that patients experienced reduction in body weight regardless of their baseline BMI (25.0--40.0 kg/m^2^) after initiating liraglutide therapy \[[@CR42], [@CR49]\]. Importantly, higher baseline BMI was associated with larger absolute weight loss in patients \[[@CR42], [@CR49]\]. Chitnis et al. \[[@CR49]\] (*N* = 3005 patients) reported larger weight reductions with increasing BMI at the 6-month follow-up (BMI ≥ 40 kg/m^2^: −4.0 kg; BMI 35--39.9 kg/m^2^: --3.0 kg; BMI 30--34.9 kg/m^2^: −1.9 kg; BMI 25--29.9 kg/m^2^: −1.5 kg; *P* \< 0.01 for trend) \[[@CR49]\]. Ponzani et al. \[[@CR42]\] (*N* = 205 patients) reported similar findings at 20 months (BMI ≥35 kg/m^2^: −6.66 kg; BMI \>30--35 kg/m^2^: −4.8 kg; BMI ≤30 kg/m^2^: −2.98 kg) \[[@CR42]\]. Both these studies had good generalizability to real-world patients with T2DM and obesity \[[@CR42], [@CR49]\]. These findings reinforce that liraglutide could be beneficial, not only in avoiding weight gain, but also in helping patients with T2DM and obesity to lose weight.

### NICE Composite Endpoint: Percentage of Patients with HbA1c Reduction ≥1% and Weight Reduction ≥3% {#Sec19}

Treatment guidelines for the management of T2DM highlight the importance of not only improving glycemic control but also of managing obesity and hypertension \[[@CR74]\]. Thus, composite endpoints are increasingly reported in the assessment of novel diabetes therapies. The NICE guidelines recommend that GLP-1 mimetic therapy is continued if patients with T2DM have a beneficial metabolic response (a reduction of at least 11 mmol/mol \[1.0%\] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months) \[[@CR74]\].

Nine full-text articles reported data on patients achieving the NICE composite endpoint with liraglutide therapy (Table [2](#Tab2){ref-type="table"}). These studies reported that the NICE composite endpoint was met in 20.1% (baseline HbA1c: 9.7% \[[@CR51]\]) to 47.0% (baseline HbA1c: 8.2% \[[@CR44]\]) of patients with T2DM who were treated with liraglutide for at least 6 months.Table 2Overview of studies reporting NICE Composite endpoint in real-world evidence studiesCodeInterventionMean baseline HbA1c (SD), %*N*Follow-up duration (months)NICE composite endpoint^b^ achievedFull-text publications Nyeland et al. 2015 \[[@CR58]\]Liraglutide8.8 (1.9)287625.10%Sitagliptin8.6 (1.5)278110.4%^a^ Heymann et al. 2014 \[[@CR51]\]Liraglutide9.7 (NA)1101620.10% Russo et al. 2015 \[[@CR44]\]Liraglutide8.2 (1.3)1151247% Evans et al. 2014 \[[@CR33]\]Liraglutide9.6 (0.5)2291232%Exenatide9.8 (0.8)14824%DPP-4i8.1 (0.4)71064% Evans et al. 2013 \[[@CR32]\]Exenatide BID9.6 (0.5)148123 months: 27%\
6 months: 24%\
9 months: 26%\
12 months: 25%\
Audit end: 21%Liraglutide9.8 (0.8)2563 months: 35%\
6 months: 32%\
9 months: 31%\
12 months: 29%\
Audit end: 28%DPP-4i (sitagliptin, saxagliptin, or vildagliptin)8.1(0.4)7103 months: 59%\
6 months: 61%\
9 months: 52%\
12 months: 54%\
Audit end: 57%Conference abstracts Heymann et al. 2013 \[[@CR80]\]Liraglutide8.7 (1.3)453620.10% Karasik et al. 2013 \[[@CR81]\]Liraglutide8.57 (1.20)614616.90% Fatima et al. 2014 \[[@CR82]\]Liraglutide8.7 (NA)43642% Mattson et al. 2015 \[[@CR79]\]Liraglutide7.69 (1.43)180627%Sitagliptin7.53 (1.50)20810%*BID* twice daily, *DPP*-*4i* dipeptidyl peptidase-4 inhibitor, *HbA1c* glycated hemoglobin, *N* number of patients, *NA* not available, *NICE* National Institute for Health and Care Excellence, *SD* standard deviation^a^ *P* \< 0.001^b^Percentage of patients with HbA1c reduction ≥1% and weight reduction ≥3%

Treatment with DPP-4i resulted in higher proportions of patients meeting the NICE composite endpoint (57--64%; baseline HbA1c: 8.1%) compared to liraglutide (28--32%; baseline HbA1c: 9.6%) and exenatide (21--24%; baseline HbA1c: 9.8%) \[[@CR32], [@CR33]\]. Notably, in these studies baseline HbA1c level of patients with T2DM was significantly different. In two other studies, despite similar baseline characteristics of patients, superior HbA1c and weight reductions with liraglutide compared to sitagliptin were reflected in routine clinical practice (25% vs. 10%, respectively) \[[@CR58], [@CR79]\]. Data from conference abstracts mirrored these findings.

Comparative Effectiveness {#Sec20}
-------------------------

Data from studies comparing liraglutide with an active comparator (sitagliptin or DPP-4i, exenatide or GLP-1 RA, pioglitazone or TZD, glimepiride or SU, and MET) were reported in eight full-text articles (Table [3](#Tab3){ref-type="table"}). Comparative effectiveness data on the effect of liraglutide on blood pressure, lipid profile, FPG, and PPG were available from a small number of studies.Table 3Comparative effectiveness of liraglutide in patients with T2DMReferences*N*Follow-up (months)PopulationStudy designTreatmentBaseline HbA1c, mean%Mean change in HbA1c from baseline,%% patients achieving HbA1c \<7%Baseline weight, mean kgMean change in weight from baseline, kgDeKoven et al. 2014 \[[@CR50]\]2346T2DMRetrospective cohortLiraglutide7.8%−1.0%64.5%NANA182Exenatide7.8%−0.7%54.40%NANAOhki et al. 2012 \[[@CR40]\]2618T2DM with NAFLDRetrospective cohortLiraglutide8.4%−0.8%NA81.8 kg−3.8 kg36Sitagliptin8.4%−1.1%NA81.1 kg−0.4 kg20Pioglitazone7.7%−0.8%NA78.6 kg3.2 kgNyeland et al. 2015 \[[@CR58]\]2876T2DMRetrospective databaseLiraglutide8.8%−0.9%29.3%114.3 kg−3.78 kg2781Sitagliptin8.6%−0.6%^a^22.8%95.4 kg−1.12 kg^b^Evans et al. 2014 \[[@CR33]\]256\
14812T2DMRetrospective cohortLiraglutide9.6%−1.23%NA109.7 kg−3.9 kgExenatide9.8%−0.79%^c^NA110.6 kg−2.9 kgDPP-4i8.1%−0.72%^c^NA88.9 kg−0.8 kg^c^Evans et al. 2013 \[[@CR32]\]25612T2DMRetrospective chart auditLiraglutide9.8%−1.28%NA109.7 kg−3.3 kg710DPP-4i8.1%−0.7%^c^NA88.9 kg−0.7 kg^c^148Exenatide9.6%−0.7%^c^NA110.6 kg−2.5 kg54DPP-4i to liraglutideNR−0.9%^c^NANR−2.5 kgNAExenatide to liraglutideNR−0.8%NANR−2.1 kgChiefari et al. 2015 \[[@CR30]\]7618T2DMRetrospective cohortLiraglutide8.1%−1.4%51.3%73.5 kg−4.00 kg103Glimepiride8.0%−0.4%^b^11.6%^b^75 kgno change^b^Li et al. 2012 \[[@CR56]\]3766T2DMRetrospective cohortLiraglutide7.9%−0.95%52%NANA1089Sitagliptin8.8%−0.7%^a^44%^a^NANAThomsen et al. 2015 \[[@CR45]\]29836T2DMRetrospective databaseLiraglutide7.9%−1.3%NANANA31ExenatideNRNRNANANA282Other GLD7.9%−0.9%NANANA1262DPP-4i7.6%−0.8%NANANA2484SU8.0%−1.2%NANANA*DPP*-*4i* dipeptidyl peptidase-4 inhibitor, *GLD* glucose-lowering drug, *HbA1c* glycated hemoglobin, *NA* not available, *NAFLD* non-alcoholic fatty liver disease, *N* number of patients, *NR* not reported, *SU* sulfonylurea, *T2DM* type 2 diabetes mellitus*P* values for liraglutide vs. active comparator: ^a^ *P* \< 0.01; ^b^ *P* \< 0.001; ^c^ *P* \< 0.05

### Change in HbA1c Level {#Sec21}

An overview of the changes in the post-interventional mean HbA1c level achieved by liraglutide treatment compared to other antidiabetic therapies is given in Table [3](#Tab3){ref-type="table"}. Overall, studies comparing liraglutide and sitagliptin showed that liraglutide patients are more likely to achieve HbA1c and weight reductions compared with sitagliptin/DPP-4i patients in routine clinical practice. Change in mean HbA1c level with liraglutide treatment was greater than that observed with sitagliptin or DPP-4i treatment \[[@CR32], [@CR33], [@CR40], [@CR45], [@CR56], [@CR58]\]. A retrospective database analysis in primary care using the Clinical Practice Research Datalink in the UK assessed the effectiveness of liraglutide treatment in patients aged ≥18 years \[[@CR58]\]. This study showed superior HbA1c and weight reductions with liraglutide compared to sitagliptin. When controlling for potential confounders, liraglutide was more likely than sitagliptin to achieve an HbA1c reduction of ≥1% \[odds ratio (OR) = 2.29, 95% confidence interval (CI): 1.62--3.25\], the composite target of HbA1c reduction ≥1% and weight reduction ≥3% (OR = 2.99; 95% CI: 2.00--4.48), and a target HbA1c \<7% (OR = 2.11; 95% CI: 1.45--3.07) after 6 months of treatment \[[@CR58]\]. In another retrospective chart audit conducted in the UK, greater changes in HbA1c were seen with liraglutide (--1.28%) in comparison with a pooled group of DPP-4i (−0.74%; *P* \< 0.05) \[[@CR32]\]. In the same study, a subgroup analysis was conducted for patients switching to liraglutide from DPP-4i which resulted in a mean HbA1c reduction of −0.9% for the liraglutide-treated patients (*P* \< 0.05 vs. DPP-4i) \[[@CR32]\]. Importantly, patients using GLP-1 RA (62.5%) had a higher baseline BMI score and HbA1c values, and longer diabetes duration than those on DPP-4i \[[@CR32]\]. In other studies, it was also observed that patients with T2DM were switching their antidiabetic treatment from DPP-4i to liraglutide \[[@CR37], [@CR51]\]. This likely reflects the superior effect of GLP-1 RA therapy compared with DPP-4i, and emphasizes the success of switching patients from a DPP-4i to a GLP-1 RA \[[@CR83], [@CR84]\].

Four studies compared the glycemic effect of liraglutide and exenatide. Overall, change in HbA1c with liraglutide was slightly greater than that observed with exenatide \[[@CR32], [@CR33], [@CR45], [@CR50]\] (Table [3](#Tab3){ref-type="table"}). Half of the studies reported statistically significant reductions in HbA1c level with liraglutide treatment compared to exenatide. Notably, patients previously receiving exenatide achieved a 0.8% HbA1c reduction from baseline when switched to liraglutide, in excess of the 0.32% reduction from baseline seen in the clinical trial switching exenatide to liraglutide. However, this may reflect suboptimal previous exenatide therapy, as the majority of these patients (62.6%) discontinued exenatide due to tolerability issues \[[@CR85]\].

#### Percentage of Patients Achieving HbA1c Recommended Targets of \<7% and ≤6.5% {#Sec22}

Four studies reported comparative data for percentage of patients achieving recommended HbA1c targets \[[@CR30], [@CR50], [@CR56], [@CR58]\], details of which are provided in Table [3](#Tab3){ref-type="table"}. Liraglutide showed better effectiveness in achieving a higher percentage of patients reaching the \<7% HbA1c goal compared to glimepiride at 18 months (51.3% vs. 11.6%; *P* \< 0.001) \[[@CR30]\] and compared to sitagliptin (29.3% vs. 22.8%; OR = 2.11, 95% CI 1.45--3.07) \[[@CR58]\]. Superior effectiveness of liraglutide compared to sitagliptin was also reported (52% vs. 44%; 6 months; OR = 1.55; *P* \< 0.01) \[[@CR56]\]. Using the HbA1c target of ≤6.5%, liraglutide treatment also resulted in a higher proportion of patients achieving the target compared to sitagliptin (37 vs. 26%; OR = 2.00; *P* \< 0.01) \[[@CR56]\].

Glucose-lowering effectiveness was comparable between liraglutide and exenatide therapy. The percentage of patients reaching \<7% HbA1c target was reported as 64.5% and 54.4% after 6 months of therapy with liraglutide and exenatide treatment, respectively (*P* = 0.04) \[[@CR50]\].

#### Body Weight {#Sec23}

Five studies provided comparative data on the weight effect of liraglutide treatment (Table [3](#Tab3){ref-type="table"}) \[[@CR30], [@CR32], [@CR33], [@CR40], [@CR58]\]. Overall, these findings demonstrated an added benefit of liraglutide therapy in achieving HbA1c and weight reductions compared with other diabetic therapies in real-world setting. Liraglutide showed superior weight reduction compared to sitagliptin \[[@CR58]\], pioglitazone \[[@CR40]\], and glimepiride \[[@CR30]\]. Furthermore, liraglutide was effective in reducing patients' weight among those with previous therapy with insulin \[[@CR62]\] or a DPP-4i class drug \[[@CR32]\].

Clinical effectiveness regarding body weight reduction was comparable between liraglutide and exenatide, though liraglutide usually led to a numerically higher body weight reduction \[[@CR32], [@CR86]\].

Tolerability and Safety {#Sec24}
-----------------------

### Overall {#Sec25}

A total of 52 publications that were identified in the literature search reported data on the AE profile of liraglutide. Of these, 26 were full-text articles. The rates of any AE ranged from 0.0% to 64.3%. Gastrointestinal AEs (nausea, vomiting, diarrhea, abdominal pain) were the most commonly reported AE type (0.51--42.9% of all reported AEs). Gastrointestinal AEs were normally reported in the first few weeks after initiating liraglutide and when present, were considered mild and transient. Skin reactions/rash and headache were uncommon (1--3%). Up to one-third of patients withdrew from the studies because of AEs (0--30%) \[[@CR29], [@CR36], [@CR37], [@CR39], [@CR41], [@CR44], [@CR47], [@CR48], [@CR52], [@CR54], [@CR55], [@CR57], [@CR62], [@CR64], [@CR67]\]. The most common reasons for withdrawal due to AEs were reported to be vomiting and nausea. From the identified full-text publications, to our knowledge only four studies reported occurrences of pancreatic disease \[[@CR29], [@CR36], [@CR37], [@CR42]\] and one study reported thyroid disease \[[@CR36]\]. Two studies reported no cases of pancreatic disease \[[@CR29], [@CR42]\]. Ghuman et al. \[[@CR37]\] reported 1 case of pancreatitis among 152 patients that were followed for up to 20 months. In the EVIDENCE study (ClinicalTrials.gov identifier: NCT01226966), 3152 patients were followed up to 24 months \[[@CR36]\], in that period 8 medical AEs related to pancreatic pathologies (pancreatitis \[*N* = 1\], acute pancreatitis \[*N* = 4\], increased lipasemia \[*N* = 1\], and hepato-pancreatic biological disorder \[*N* = 1\]) and eight AEs linked to thyroid pathologies (goiter \[*N* = 2\], hyperthyroidism \[*N* = 1\], hypothyroidism \[*N* = 1\], thyroid disorder \[*N* = 1\], thyroid nodule \[*N* = 1\], thyroid cancer \[non-encapsulated papillary carcinoma; *N* = 1\], and thyroidectomy with no known etiology \[*N* = 1\]) were reported. In this observational study, one patient died of pancreatic tumor 4 months after starting treatment with liraglutide. Funch et al. \[[@CR35]\] assessed the relationship between liraglutide and acute pancreatitis or pancreatic cancer in a post-marketing safety assessment program and reported no increased risk for acute pancreatitis or pancreatic cancer in association with liraglutide therapy. Hyperglycemic events were not reported in any of the publications covered by this review.

### Hypoglycemia {#Sec26}

Twenty-six publications reported data on hypoglycemia (Table [4](#Tab4){ref-type="table"}). Of these, 17 were full-text articles. Data from full-text articles showed that hypoglycemia-related events, including minor hypoglycemia, occurred at low rates (0.0--15.2%). Symptomatic hypoglycemia occurred in 0.8% of patients with liraglutide treatment and the occurrence of major (severe) hypoglycemia was rare. In patients who received liraglutide monotherapy, the rate of episodes of hypoglycemia did not exceed 0.8%.Table 4Occurrence of hypoglycemiaReferencesIntervention (concomitant medication)Follow-up duration*N*Hypoglycemic episodesGautier et al. 2015 \[[@CR36]\]Liraglutide (OADs)24 months3152\
2 years: 20093 months: 7.4%\
2 years: 4.4%Toyoda et al. 2014 \[[@CR61]\]Liraglutide (SU)6 months3800.0%Mori et al. 2011 \[[@CR68]\]  Liraglutide (OADs)NA8% time in hypoglycemia (24-h) at pre-treatment: 0.1 (0.3)%0.3 mg% time in hypoglycemia (24-h): 0.5 (1.7)%0.6 mg% time in hypoglycemia (24-h): 0.1 (0.2)%0.9 mg% time in hypoglycemia (24-h): 0.4 (1.3)%Liraglutide only12% time in hypoglycemia (24-h): 0.0 (0.0)%0.3 mg% time in hypoglycemia (24-h): 0.0 (0.1)%0.6 mg% time in hypoglycemia (24-h): 0.0 (0.0)%0.9 mg% time in hypoglycemia (24-h): 0.0 (0.0)%Usui et al. 2013 \[[@CR70]\]Liraglutide (SU)3 months1470.0%Li et al. 2014 \[[@CR56]\]  Liraglutide (OADs)6 months376Severe: 0.5%Sitagliptin (OADs)1089Severe: 0.61% (*P* = 0.81; between groups)Mezquita-Raya et al. 2015 \[[@CR57]\]Liraglutide (OADs)6 months740All: 7.8%\
Severe: 0.0%\
Patients with insulin plus liraglutide: 10.6%\
Patients with secretagogues plus liraglutide: 15.2% (*P* = 0.369 vs. insulin plus liraglutide)\
Patients with MET plus liraglutide: 1.6% (*P* \< 0.001 vs. insulin/secretagogues plus liraglutide)Buysschaert et al. 2015 \[[@CR29]\]Liraglutide (MET and SU)12 months245Minor: 0.07 to 0.55 events per patient per month\
Major: 1 event at 3 monthsKesavadev et al. 2012 \[[@CR53]\]Liraglutide (OADs)6 months140.0%Mulligan et al. 2013 \[[@CR69]\]Liraglutide (SU; insulin)4 months193Minor: 5.7% (81.8% on concomitant SUs; 0.09% patients on basal insulin)Chitnis et al. 2014 \[[@CR49]\]Liraglutide only6 months30050.2--0.7%Cotugno et al. 2015 \[[@CR31]\]Liraglutide only12 months310.0%Evans et al. 2014 \[[@CR33]\]Liraglutide only12 months256Symptomatic: 0.8%Exenatide148Symptomatic: 0.9%DDP-4i710Symptomatic: 0.8%Vitagliano et al. 2014 \[[@CR46]\]BS12 months28Symptomatic reactive: 28.5%Liraglutide only220.0%Evans et al. 2013 \[[@CR32]\]DPP-4i12 months710Symptomatic: 0.8%Exenatide148Symptomatic: 0.9%Liraglutide only256Symptomatic: 0.8%Kaur et al. 2014 \[[@CR67]\]Liraglutide (OADs)3 months196Minor: 3.0%Lapolla et al. 2015 \[[@CR39]\]Liraglutide (OADs)12 months4815.0%Chiefari et al. 2015 \[[@CR30]\]Liraglutide (MET, MET plus insulin)18 months76Major: 0.0%\
Minor: 2.6%Glimepiride103Major: 2.9%, *P* = 0.263 (between groups)\
Minor: 18.4%, *P* \< 0.001 (between groups)*DPP*-*4i* dipeptidyl peptidase-4 inhibitor, *MET* metformin, *N* number of patients, *OAD* oral antidiabetic drug, *SU* sulfonylurea*OptumInsight*™ and *HealthCore* ^®^ are two major US healthcare companies' administrative claims databases

Hypoglycemia was more often reported in studies with liraglutide combination therapy. Nineteen studies reported hypoglycemia episodes most frequently when liraglutide was added to MET, SU, insulin, or other OADs (0.0--15.2%).

Overall results from conference abstracts echoed the conclusions from full-text publications.

Data from comparative studies showed similar rates of hypoglycemia in all treatment groups, except for glimepiride compared to liraglutide (18.4% vs. 2.9%; *P* \< 0.001) \[[@CR30]\]. Rates of hypoglycemia did not vary at different follow-up durations. A real-world study \[[@CR36]\] that followed patients with T2DM who were on liraglutide treatment for 24 months reported a hypoglycemia rate of 4.4% (*N* = 2009 patients) \[[@CR36]\]. Notably, no correlation between the occurrence of hypoglycemia and liraglutide dosage (1.2 mg or 1.8 mg) was observed \[[@CR36]\].

Discussion {#Sec27}
==========

This systematic review reports evidence of the effectiveness of liraglutide in T2DM treatment in real-world clinical practice. The main findings presented in this review were obtained from full-text journal articles. The results of the identified conference proceedings in the last 3 years were consistent with those of full text articles.

Overall, liraglutide was demonstrated to be an effective (i.e., reduced HbA1c and body weight) treatment for patients with T2DM. Clinical effectiveness of liraglutide treatment was shown in patients at T2DM with continued liraglutide therapy (at least 12 months), and was well tolerated in these patients in real-life clinical practice.

Glucose Control {#Sec28}
---------------

Real-life use of liraglutide confirmed good control of HbA1c level among patients with T2DM (7413 patients treated with liraglutide), measured by absolute change of HbA1c level, the percentage of patients reaching HbA1c treatment target (\<7% or ≤6.5%), and the NICE composite endpoint. In real-world clinical practice, liraglutide treatment (alone or in combination with other glucose-lowering therapies) significantly reduces HbA1c (change in mean HbA1c: −0.9% to −2.26%). This change in HbA1c was clinically relevant and corresponded well with that reported in the randomized controlled trials (RCTs; −0.8% to −1.83%) \[[@CR11]--[@CR25]\]. Among the included studies, at least one-third of patients on liraglutide therapy reached the HbA1c \<7.0% target (29.5--65.0%), which is comparable to the proportion (35.0--45.0%) of patients reaching the HbA1c target reported after 26 weeks of liraglutide treatment in the LEAD RCTs \[[@CR11]--[@CR16]\]. The beneficial effect of liraglutide treatment on FPG and PPG in patients with T2DM was also demonstrated in the real-world setting.

The NICE composite endpoint was met in 16.90--47.0% of patients with T2DM who initiated liraglutide therapy in real-life clinical practice. The average decrease in HbA1c was approximately 1% regardless of baseline HbA1c level. We identified 3 studies, with a total of 268 patients treated with liraglutide, investigating the effectiveness of liraglutide using different doses of (0.3--1.8 mg) \[[@CR43], [@CR57], [@CR68]\], which also reflects the choice of doses in different countries. Based on this limited number of patients, it seems that HbA1c change from baseline to post-intervention does not differ substantially between different doses \[[@CR43], [@CR57]\]. However, escalating liraglutide dose to 1.8 mg in patients who do not respond to the 1.2 mg dose resulted in an additional decrease in HbA1c (−0.62% ± 0.17%; *P* \< 0.05 vs. liraglutide 1.2 mg) \[[@CR43]\]. Dose escalation to 1.8 mg also helped further body weight reduction \[[@CR43]\].

Body Weight {#Sec29}
-----------

Real-world studies showed substantial changes in body weight (−1.3 to −8.65 kg). Studies showed that patients experienced reduction in body weight regardless of their baseline BMI (25.0--40.0 kg/m^2^) after initiating liraglutide therapy \[[@CR42], [@CR49]\]. In addition to this, higher BMI at baseline was associated with slightly greater weight loss with liraglutide treatment \[[@CR42], [@CR49]\]. The effect of such weight loss in patients with T2DM remains to be demonstrated; however, this finding reveals that liraglutide may help in improving patient quality of life in patients with T2DM with overweight or obesity \[[@CR42], [@CR49]\]. Statistically significant and numerically larger reductions in BMI were demonstrated.

It is important to note that both glycemic control and weight effect of liraglutide in patients with T2DM were maintained with at least 12 months of liraglutide treatment \[[@CR29], [@CR38], [@CR39], [@CR42], [@CR45], [@CR49], [@CR78]\].

Comparative Effectiveness {#Sec30}
-------------------------

Our review identified a few studies which showed a beneficial effect of liraglutide both in terms of glycemic and weight control when patients switched from DPP-4i \[[@CR32], [@CR37], [@CR51]\]. Generally, liraglutide achieved better reductions in HbA1c and weight control in patients with T2DM compared with continuing DPP-4i/sitagliptin \[[@CR58], [@CR79]\], exenatide \[[@CR32], [@CR33]\], glimepiride, and pioglitazone.

Safety {#Sec31}
------

The safety profile of liraglutide was assessed based on the systematic literature search that included effectiveness outcomes as primary endpoints. Overall, the safety profile of liraglutide assessed in this review of real-world studies was observed to be in line with what is reported in the summary of product characteristics (SmPC) for liraglutide \[[@CR87]\]. The occurrence of acute pancreatitis reported in the EVIDENCE study (0.1%) is in agreement with the SmPC for liraglutide (\<0.2%) \[[@CR87]\]. The findings in this review confirm that liraglutide could be safely used in real-world clinical practice also in combination with other OADs. The safety data corroborate findings from clinical trials of liraglutide \[[@CR88], [@CR89]\] (AEs ranged from 0.0% to 64.3% in real-world observational studies compared to 33.0--56.0% in the LEAD RCTs) \[[@CR11]--[@CR16]\]. Safety findings were also in line with other RCTs assessing liraglutide \[[@CR17]--[@CR25]\]. For a detailed assessment of the real-world safety profile of liraglutide, a new systematic literature search specifying safety specific outcomes would be needed as this was not within the scope of the present review.

Biases and Confounding Factors in Observational Studies {#Sec32}
-------------------------------------------------------

Although this review found comparable effectiveness and safety profile of liraglutide in the real-world and RCT settings, it is important to note the difference in patient groups in observational studies and the LEAD trials with regard to patient baseline characteristics such as duration of T2DM, baseline Hba1c level, and BMI. Compared to the disease duration of patients enrolled in the LEAD trials (5.2--9.0 years), the average duration of T2DM in patients in real-world setting was longer (5--15.8 years), suggesting that patients were in a slightly later stage of T2DM. The LEAD program showed that liraglutide works in the continuum of T2DM, and may provide greater benefit when used earlier in the course of disease progression \[[@CR11]--[@CR16]\]. Additionally, patients with T2DM in the real-world setting had a higher baseline HbA1c (7.5--9.8%) and BMI (24.7--38.6 kg/m^2^) compared to the LEAD clinical trials (baseline HbA1c: 8.1--8.6%; and baseline BMI: 29.8--33.5 kg/m^2^) \[[@CR88]\], suggesting more severe disease and overweight/obesity in T2DM real-world setting. Thus, liraglutide is likely to show better clinical effectiveness in real-world studies than that reported in RCTs if used in patient groups with similar disease duration and baseline disease severity.

Merits and Limitations of This Review {#Sec33}
-------------------------------------

This systematic literature review conducted according to NICE guidelines is the first of its kind to summarize evidence on the real-world use of liraglutide. Merits of this systematic literature review include its a priori design---set inclusion and exclusion criteria, parallel screening review performed independently by two reviewers, and stringent quality control and assessment. All the parameters and clinical endpoints (i.e., HbA1c thresholds) reported were consistent with those used in clinical trials. Most of the studies were of good quality based on the quality assessment of the study design and methodology. The reporting quality of the full-text journal articles was consistent in relation to endpoints and use of liraglutide. There were a few drawbacks with the quality of the included studies. The majority of studies included in this review had a moderate sample size and were based on existing data. Most of the studies were also designed as non-comparative studies and need to be interpreted carefully as they might present some limitations in terms of bias and confounding. Despite these limitations, a similar pattern showing benefits of liraglutide on HbA1c and weight is seen in real-world clinical practice, which overall supports the findings from RCTs \[[@CR11]--[@CR16]\].

Conclusions {#Sec34}
===========

Overall, the systematic literature review of real-world observational studies reaffirms the findings from clinical trials that liraglutide monotherapy or combination therapy with other OADs translates into therapeutic benefits for patients with T2DM in routine clinical practice.
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